Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan.


Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 23 03 2019
accepted: 23 08 2019
pubmed: 5 9 2019
medline: 20 5 2020
entrez: 5 9 2019
Statut: ppublish

Résumé

Current strategies for the treatment of endometrial cancer in older adult patients require re-evaluation given the global trend in population aging, especially in Japan. We sought to evaluate initial treatment offered to older adult patients with endometrial cancer in Japan. We retrospectively analyzed data on the standard treatment by age group in patients with endometrial cancer who underwent surgery between January 2005 and December 2013 at the National Cancer Center Hospital (Tokyo, Japan). Patients were stratified into four groups according to age: a younger group, aged 64 years or younger; older adult group 1, aged 65-69 years; older adult group 2, aged 70-74 years; and older adult group 3, aged ≥75 years. Among 551 patients with endometrial cancer diagnosed and treated at our hospital, data from 531 eligible patients were analyzed. The proportion of patients in the older adult groups 1 or 2 who received standard treatment was the same as in the younger group. However, significantly fewer patients in older adult group 3 received standard treatment compared with the younger group (26% vs. 71%, p = 0.0001). Furthermore, the proportion of patients in older adult group 3 who underwent standard surgery was significantly lower than that in the younger group (26% vs. 72%, p = 0.0001). The results indicate that age 75 years and older might represent a cutoff for the development of age-based treatment strategies for endometrial cancer. This information could be used to determine the upper age limit for participation in clinical trials in Japan.

Identifiants

pubmed: 31482227
doi: 10.1007/s00280-019-03938-8
pii: 10.1007/s00280-019-03938-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1058

Auteurs

Mayu Yunokawa (M)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. mayu.yunokawa@jfcr.or.jp.
Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, Koutou-ku, Tokyo, 135-8550, Japan. mayu.yunokawa@jfcr.or.jp.

Shinsuke Sasada (S)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Yae Takehara (Y)

Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

Kenta Takahashi (K)

Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

Tatsunori Shimoi (T)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Kan Yonemori (K)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Mitsuya Ishikawa (M)

Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

Tomoyasu Kato (T)

Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

Kenji Tamura (K)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH